VXX 401
Alternative Names: Anti-PCSK9 vaccine - Vaxxinity; PCSK 9 inhibitor vaccine - Vaxxinity; VXX-401Latest Information Update: 21 Feb 2024
At a glance
- Originator Vaxxinity
- Class Antihyperlipidaemics; Peptide vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Hypercholesterolaemia
Most Recent Events
- 15 Feb 2024 Pharmacodynamics data from preclinical trial in Hypercholesterolaemia released by Vaxxinity
- 09 Aug 2023 Vaxxinity completes enrolment in its phase I trial for Hypercholesterelomia (Prevention) in Australia (IM) (NCT05762276)
- 20 Mar 2023 Safety, Immunogenicity and pharmacodynamics data from a preclinical trial in Hypercholesterolemia released by Vaxxinity